Pasar al contenido principal

Targeting chromatin-associated proteins in cancers

RYC2020-029098-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 14
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biliary tract cancers: addressing healthcare disparities and improving access to innovative treatments in Europe

  • Boilève, Alice
  • Turpin, Anthony
  • TIAN, TIAN
  • Neuzillet, Cindy
Biliary tract cancers: Disparities; Healthcare, Cánceres de las vías biliares: Disparidades; Atención sanitaria, Càncers de les vies biliars; Disparitats; Atenció sanitària, TVT is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, and Fundación AstraZeneca.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

  • Serra Camprubi, Queralt
  • Verdaguer Mata, Helena
  • Oliveros, Winona
  • Lupión-Garcia, Núria
  • Llop Guevara, Alba
  • Vila Casadesus, Maria
  • Querol Paños, Jessica
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Serra Elizalde, Violeta
  • Arribas López, Joaquin Vicente
  • Tabernero, Josep
  • Peiro Sales, Sandra
  • Tian, Tian V
  • Bernadó Morales, Cristina
  • Arenas Lahuerta, Enrique Javier
  • Frigola Rissech, Joan
  • Fabregat Franco, Carles
  • Castet, Florian
  • Miquel Aymar, Josep Maria
  • Escudero Iriarte, Carmen
  • Yáñez, Mariana
  • Escorihuela Baez, Marta
  • Macarulla Mercadé, Teresa
  • Molina, Cristina
Human metastatic cholangiocarcinoma; Xenografts; Tumoroids, Colangiocarcinoma metastàtic humà; Xenoempelts; Tumoroides, Colangiocarcinoma metastásico humano; Xenoinjertos; Tumoroides, Purpose: Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A/B, BAP1, and BRCA1/2 have been identified in 30%–50% of patients with CCA. Several types of tumor cells harboring these mutations exhibit homologous recombination deficiency (HRD) phenotype with enhanced sensitivity to PARP inhibitors (PARPi). However, PARPi treatment has not yet been tested for effectiveness in patient-derived models of advanced CCA. Experimental Design: We have established a collection of patient-derived xenografts from patients with unresectable metastatic CCA (CCA_PDX). The CCA_PDXs were characterized at both histopathologic and genomic levels. We optimized a protocol to generate CCA tumoroids from CCA_PDXs. We tested the effects of PARPis in both CCA tumoroids and CCA_PDXs. Finally, we used the RAD51 assay to evaluate the HRD status of CCA tissues. Results: This collection of CCA_PDXs recapitulates the histopathologic and molecular features of their original tumors. PARPi treatments inhibited the growth of CCA tumoroids and CCA_PDXs with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1. In line with these findings, only CCA_PDX and CCA patient biopsy samples with mutations of BRCA2 showed RAD51 scores compatible with HRD. Conclusions: Our results suggest that patients with advanced CCA with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1, are likely to benefit from PARPi therapy. This collection of CCA_PDXs provides new opportunities for evaluating drug response and prioritizing clinical trials., This work was supported by grants from the Fundació Marató TV3 awarded to T. Macarulla, M. Melé, and S. Peiró; BeiGene research grant awarded to T. Macarulla and S. Peiró; AECC (INVES20036TIAN), Ramón y Cajal investigator program (RYC2020-029098-I), Proyecto de I+D+i (PID2019-108008RJ-I00), and FERO Foundation grant awarded to T.V. Tian; Proyecto de Investigación en Salud from the Instituto de Salud Carlos III (ISCIII) (PI20/00898) awarded to T. Macarulla; FIS/FEDER from the Instituto de Salud Carlos III (ISCIII) (PI12/01250; CP08/00223; PI16/00253 and CB16/12/00449) awarded to S. Peiró; and Ramón y Cajal investigator program (RYC-2017-22249) awarded to M. Melé. Q. Serra-Camprubí is a recipient of the Ph.D. fellowship from La Caixa Foundation (LCF/PR/PR12/51070001). A. Llop-Guevara was supported by the AECC (INVES20095LLOP) and V. Serra by the ISCIII (CPII19/00033). E.J. Arenas was funded by the AECC (POSTD211413AREN). J. Arribas is funded by the Instituto de Salud Carlos III (AC15/00062, CB16/12/00449, and PI22/00001). This publication is based upon the work of COST Action CA18122, European Cholangiocarcinoma Network, supported by the COST (European Cooperation in Science and Technology, www.cost.eu), a funding agency for research and innovation networks. The authors would like to thank Dr. V.A. Raker for manuscript editing and Drs. N. Herranz and J. Mateo for scientific discussions. The authors acknowledge the infrastructure and support of the FERO Foundation, La Caixa Foundation, and the Cellex Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy

  • Zhao, Xuesong
  • Hao, Qianyun
  • Acosta, Daniel
  • Terán-Brage, Eduardo
  • Macarulla, Teresa
  • Alsina, Maria
  • Castet, Florian
  • Vega, kreina
  • Castro Boix, Sandra
  • TIAN, TIAN
Asia-West disparities; Chemotherapy; Gastric cancer, Disparidades entre Asia y Occidente; Quimioterapia; Cáncer gástrico, Disparitats entre Àsia i Occident; Quimioteràpia; Càncer gàstric, Gastric cancer (GC) remains a significant global health burden. Both Asian countries and Western nations, represented by Europe and North America, have long been pioneers in GC research and continue to lead advancements in the field. However, notable differences have historically existed between these regions in the treatment of resectable GC. In recent years, increasing convergence between Asian and Western approaches has emerged, driven by the growth of global collaborative studies. New definitive evidence suggests that the therapeutic landscape for resectable GC may undergo a significant transformation. In this review, we comprehensively examine the evolution of surgical approaches and perioperative chemotherapy strategies in Asia and the West. We summarize key clinical trials, highlight persistent survival disparities, and provide insight into current trends in perioperative management, including the recent advances in molecularly driven perioperative treatments. Finally, we outline key considerations for future multicenter perioperative trials to further guide global clinical practice., X.Z. is supported by grants from the Peking University People's Hospital (RDJP2024-20). T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation, and Universities (PID2023-146827OB-I00), the “Ramon y Cajal” program (RYC2020-029098-I), and the FERO Foundation. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

  • Llorente, Sofía
  • TIAN, TIAN
  • Lamarca, Angela
Neuregulin 1 fusions; Solid tumors, Fusiones de neuregulina; Tumores sólidos, Fusions de neuregulina; Tumors sòlids, S.L. is supported by AGAUR-FI Joan Oró fellowship (2024 FI-1 00399) from the Generalitat de Catalunya. A.L. is supported by grants from the Fundación AstraZeneca “Jóvenes Investigadores” program. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis

  • Conti, Sefora
  • Basagana, Míriam
  • Pando Rau, Elizabeth
  • Caritá, Lorenzo
  • Villacampa Javierre, Guillermo
  • Tissera, Natalia Soledad
  • Castet, Florian
  • Salcedo, Maria-Teresa
  • DOPAZO, CRISTINA
  • Navarro Garces, Victor
  • TIAN, TIAN
  • Macarulla, Teresa
Anatomic location; Cholangiocarcinoma; Disease-free survival, Localització anatòmica; Colangiocarcinoma; Supervivència lliure de malaltia, Localización anatómica; Colangiocarcinoma; Supervivencia libre de enfermedad, Background & Aims Cholangiocarcinoma (CCA), a heterogeneous malignancy that includes intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, often exhibits perineural invasion (PNI). Despite PNI being associated with postoperative recurrence, evidence on its prognostic impact remains inconsistent. To clarify this, we conducted a systematic review and meta-analysis. Methods A comprehensive literature search was conducted across the Medline-PubMed, Embase, and Web of Science databases from their inception through February 27, 2025. We included studies involving patients diagnosed with CCA who underwent surgery and for whom PNI data were available. The primary outcomes were overall survival (OS) and disease-free survival (DFS), extracted from both univariable and multivariable analyses. The study is registered in PROSPERO (CRD42024575458). Results Of 1,555 articles screened, 64 retrospective studies comprising 15,543 patients were included. In the univariable analysis, the pooled hazard ratio (HR) for OS from 34 studies (6,084 patients) was 1.92 (95% CI 1.67-2.21, I2 = 59.6%). Multivariable-adjusted analysis of 42 studies (10,335 patients) showed an HR of 1.68 (95% CI 1.47-1.90, I2 = 47.9%) for patients with PNI. For DFS, the pooled univariable HR in 6,110 patients was 1.70 (95% CI 1.46-1.98, I2 = 52.3%), and the multivariable HR was 1.62 (95% CI 1.37-1.92, I2 = 70.5%)). Prognostic consistency was observed across anatomical subgroups. Univariable OS HRs were 2.14 for iCCA, 1.69 for pCCA, and 1.66 for dCCA. Corresponding multivariable HRs were 1.74, 1.60, and 1.66, respectively. Conclusions PNI is a prognostic factor for both DFS and OS in CCA, regardless of anatomical location. Further research is needed to elucidate its biological mechanisms and potential therapeutic implications. Impact and implications This comprehensive review and meta-analysis confirms that perineural invasion (PNI) predicts poorer overall and disease-free survival in cholangiocarcinoma, independent of tumor location. These results highlight the potential of PNI as a reliable histopathological marker to stratify postoperative risk and inform patient management. While most evidence is retrospective and smaller studies may overstate the effect, the consistent findings emphasize the need for large, multicenter prospective studies with standardized pathological assessment. Such efforts could facilitate the integration of PNI into prognostic models and support more individualized treatment strategies for patients with cholangiocarcinoma., S.C. is supported by a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (JDC2023-050981-I). N.T. is supported by a La Pedrera MD-PhD fellowship from the Fundació Catalunya La Pedrera. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer

  • Pascual-Reguant, Laura, 1990-
  • Datta, Debayan
  • Cianferoni, Damiano
  • Kourtis, Savvas
  • Gañez-Zapater, Antoni
  • Cannatá, Chiara
  • Espinar, Lorena
  • García López, Laura
  • Musa-Afaneh, Sara
  • Guirola, Maria
  • Gkanogiannis, Anestis
  • Miró Canturri, Andrea
  • Arribas, Joaquín
  • Serrano Pubull, Luis, 1982-
  • Sdelci, Sara
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically limits TNBC proliferation in vitro and in vivo. Mechanistically, LOXL2 interacts in the nucleus with the short isoform of BRD4 (BRD4S), MED1, and the cell cycle transcriptional regulator B-MyB. These interactions sustain the formation of BRD4 and MED1 nuclear transcriptional foci and control cell cycle progression at the gene expression level. The pharmacological co-inhibition of LOXL2 and BRD4 reduces BRD4 nuclear foci, BRD4-MED1 colocalization, and the transcription of cell cycle genes, thus suppressing TNBC cell proliferation. Targeting the interaction between BRD4S and LOXL2 could be a starting point for the development of new anticancer strategies for the treatment of TNBC., We thank Pharmaxis for the supply of PXS LOXL2 inhibitors. SS is supported by the Plan Estatal de I + D + I (COMBAT PID2019‐110598GA‐I00), and the ERC Starting Grant (ERC‐StG‐852343‐EPICAMENTE). LP‐R is supported by the Juan de la Cierva‐Formación fellowship (FJC2019‐040598‐I) and Fundación Franscico Cobos fellowship. TVT is supported by Plan Estatal de I + D + I (PID2019‐108008RJ‐I00), AECC (INVES20036TIAN), and a Ramón y Cajal investigator contract (RYC2020‐029098‐I). DC is supported by the la Caixa Foundation PhD fellowship (ID 100010434; fellowship code LCF/BQ/DI19/11730061).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Biliary tract cancers: addressing healthcare disparities and improving access to innovative treatments in Europe

  • Boilève, Alice
  • Turpin, Anthony
  • TIAN, TIAN
  • Neuzillet, Cindy
Biliary tract cancers: Disparities; Healthcare, Cánceres de las vías biliares: Disparidades; Atención sanitaria, Càncers de les vies biliars; Disparitats; Atenció sanitària, TVT is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, and Fundación AstraZeneca.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The potential of patient-derived organoids in precision medicine of biliary tract cancer

  • Yáñez, Mariana
  • TIAN, TIAN
  • Macarulla, Teresa
Organoids; Precision; Biliary tract cancer, Organoides; Medicina de precisión; Cáncer de vías biliares, Organoides; Medicina de precisió; Càncer de vies biliars, Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al.1 developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation of chemotherapy response prediction., This work is supported by grants from the EU Transcan-3 project (SIMMBAP), Instituto de Salud Carlos III (PMP22/00054 and PI20/00898) awarded to T.M., and grants from Asociación Española Contra el Cáncer (AECC), Ministerio de Ciencia e Innovación de España (RYC2020-029098-I and PID2019-108008RJ-I00), and FERO Foundation awarded to T.V.T.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

  • Serra Camprubi, Queralt
  • Verdaguer Mata, Helena
  • Oliveros, Winona
  • Lupión-Garcia, Núria
  • Llop Guevara, Alba
  • Vila Casadesus, Maria
  • Querol Paños, Jessica
  • Nuciforo, Paolo Giovanni
  • Vivancos Prellezo, Ana
  • Serra Elizalde, Violeta
  • Arribas López, Joaquin Vicente
  • Tabernero, Josep
  • Peiro Sales, Sandra
  • Tian, Tian V
  • Bernadó Morales, Cristina
  • Arenas Lahuerta, Enrique Javier
  • Frigola Rissech, Joan
  • Fabregat Franco, Carles
  • Castet, Florian
  • Miquel Aymar, Josep Maria
  • Escudero Iriarte, Carmen
  • Yáñez, Mariana
  • Escorihuela Baez, Marta
  • Macarulla Mercadé, Teresa
  • Molina, Cristina
Human metastatic cholangiocarcinoma; Xenografts; Tumoroids, Colangiocarcinoma metastàtic humà; Xenoempelts; Tumoroides, Colangiocarcinoma metastásico humano; Xenoinjertos; Tumoroides, Purpose: Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2, ARID1A/B, BAP1, and BRCA1/2 have been identified in 30%–50% of patients with CCA. Several types of tumor cells harboring these mutations exhibit homologous recombination deficiency (HRD) phenotype with enhanced sensitivity to PARP inhibitors (PARPi). However, PARPi treatment has not yet been tested for effectiveness in patient-derived models of advanced CCA. Experimental Design: We have established a collection of patient-derived xenografts from patients with unresectable metastatic CCA (CCA_PDX). The CCA_PDXs were characterized at both histopathologic and genomic levels. We optimized a protocol to generate CCA tumoroids from CCA_PDXs. We tested the effects of PARPis in both CCA tumoroids and CCA_PDXs. Finally, we used the RAD51 assay to evaluate the HRD status of CCA tissues. Results: This collection of CCA_PDXs recapitulates the histopathologic and molecular features of their original tumors. PARPi treatments inhibited the growth of CCA tumoroids and CCA_PDXs with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1. In line with these findings, only CCA_PDX and CCA patient biopsy samples with mutations of BRCA2 showed RAD51 scores compatible with HRD. Conclusions: Our results suggest that patients with advanced CCA with pathogenic mutations of BRCA2, but not those with mutations of IDH1, ARID1A, or BAP1, are likely to benefit from PARPi therapy. This collection of CCA_PDXs provides new opportunities for evaluating drug response and prioritizing clinical trials., This work was supported by grants from the Fundació Marató TV3 awarded to T. Macarulla, M. Melé, and S. Peiró; BeiGene research grant awarded to T. Macarulla and S. Peiró; AECC (INVES20036TIAN), Ramón y Cajal investigator program (RYC2020-029098-I), Proyecto de I+D+i (PID2019-108008RJ-I00), and FERO Foundation grant awarded to T.V. Tian; Proyecto de Investigación en Salud from the Instituto de Salud Carlos III (ISCIII) (PI20/00898) awarded to T. Macarulla; FIS/FEDER from the Instituto de Salud Carlos III (ISCIII) (PI12/01250; CP08/00223; PI16/00253 and CB16/12/00449) awarded to S. Peiró; and Ramón y Cajal investigator program (RYC-2017-22249) awarded to M. Melé. Q. Serra-Camprubí is a recipient of the Ph.D. fellowship from La Caixa Foundation (LCF/PR/PR12/51070001). A. Llop-Guevara was supported by the AECC (INVES20095LLOP) and V. Serra by the ISCIII (CPII19/00033). E.J. Arenas was funded by the AECC (POSTD211413AREN). J. Arribas is funded by the Instituto de Salud Carlos III (AC15/00062, CB16/12/00449, and PI22/00001). This publication is based upon the work of COST Action CA18122, European Cholangiocarcinoma Network, supported by the COST (European Cooperation in Science and Technology, www.cost.eu), a funding agency for research and innovation networks. The authors would like to thank Dr. V.A. Raker for manuscript editing and Drs. N. Herranz and J. Mateo for scientific discussions. The authors acknowledge the infrastructure and support of the FERO Foundation, La Caixa Foundation, and the Cellex Foundation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

From obscurity to opportunity: targeting Neuregulin 1 fusions in solid tumors

  • Llorente, Sofía
  • TIAN, TIAN
  • Lamarca, Angela
Neuregulin 1 fusions; Solid tumors, Fusiones de neuregulina; Tumores sólidos, Fusions de neuregulina; Tumors sòlids, S.L. is supported by AGAUR-FI Joan Oró fellowship (2024 FI-1 00399) from the Generalitat de Catalunya. A.L. is supported by grants from the Fundación AstraZeneca “Jóvenes Investigadores” program. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and University (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy

  • Zhao, Xuesong
  • Hao, Qianyun
  • Acosta, Daniel
  • Terán-Brage, Eduardo
  • Macarulla, Teresa
  • Alsina, Maria
  • Castet, Florian
  • Vega, kreina
  • Castro Boix, Sandra
  • TIAN, TIAN
Asia-West disparities; Chemotherapy; Gastric cancer, Disparidades entre Asia y Occidente; Quimioterapia; Cáncer gástrico, Disparitats entre Àsia i Occident; Quimioteràpia; Càncer gàstric, Gastric cancer (GC) remains a significant global health burden. Both Asian countries and Western nations, represented by Europe and North America, have long been pioneers in GC research and continue to lead advancements in the field. However, notable differences have historically existed between these regions in the treatment of resectable GC. In recent years, increasing convergence between Asian and Western approaches has emerged, driven by the growth of global collaborative studies. New definitive evidence suggests that the therapeutic landscape for resectable GC may undergo a significant transformation. In this review, we comprehensively examine the evolution of surgical approaches and perioperative chemotherapy strategies in Asia and the West. We summarize key clinical trials, highlight persistent survival disparities, and provide insight into current trends in perioperative management, including the recent advances in molecularly driven perioperative treatments. Finally, we outline key considerations for future multicenter perioperative trials to further guide global clinical practice., X.Z. is supported by grants from the Peking University People's Hospital (RDJP2024-20). T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation, and Universities (PID2023-146827OB-I00), the “Ramon y Cajal” program (RYC2020-029098-I), and the FERO Foundation. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Perineural invasion is a prognostic factor in cholangiocarcinoma, regardless of anatomical location: A systematic review and meta-analysis

  • Conti, Sefora
  • Basagana, Míriam
  • Pando Rau, Elizabeth
  • Caritá, Lorenzo
  • Villacampa Javierre, Guillermo
  • Tissera, Natalia Soledad
  • Castet, Florian
  • Salcedo, Maria-Teresa
  • DOPAZO, CRISTINA
  • Navarro Garces, Victor
  • TIAN, TIAN
  • Macarulla, Teresa
Anatomic location; Cholangiocarcinoma; Disease-free survival, Localització anatòmica; Colangiocarcinoma; Supervivència lliure de malaltia, Localización anatómica; Colangiocarcinoma; Supervivencia libre de enfermedad, Background & Aims Cholangiocarcinoma (CCA), a heterogeneous malignancy that includes intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) subtypes, often exhibits perineural invasion (PNI). Despite PNI being associated with postoperative recurrence, evidence on its prognostic impact remains inconsistent. To clarify this, we conducted a systematic review and meta-analysis. Methods A comprehensive literature search was conducted across the Medline-PubMed, Embase, and Web of Science databases from their inception through February 27, 2025. We included studies involving patients diagnosed with CCA who underwent surgery and for whom PNI data were available. The primary outcomes were overall survival (OS) and disease-free survival (DFS), extracted from both univariable and multivariable analyses. The study is registered in PROSPERO (CRD42024575458). Results Of 1,555 articles screened, 64 retrospective studies comprising 15,543 patients were included. In the univariable analysis, the pooled hazard ratio (HR) for OS from 34 studies (6,084 patients) was 1.92 (95% CI 1.67-2.21, I2 = 59.6%). Multivariable-adjusted analysis of 42 studies (10,335 patients) showed an HR of 1.68 (95% CI 1.47-1.90, I2 = 47.9%) for patients with PNI. For DFS, the pooled univariable HR in 6,110 patients was 1.70 (95% CI 1.46-1.98, I2 = 52.3%), and the multivariable HR was 1.62 (95% CI 1.37-1.92, I2 = 70.5%)). Prognostic consistency was observed across anatomical subgroups. Univariable OS HRs were 2.14 for iCCA, 1.69 for pCCA, and 1.66 for dCCA. Corresponding multivariable HRs were 1.74, 1.60, and 1.66, respectively. Conclusions PNI is a prognostic factor for both DFS and OS in CCA, regardless of anatomical location. Further research is needed to elucidate its biological mechanisms and potential therapeutic implications. Impact and implications This comprehensive review and meta-analysis confirms that perineural invasion (PNI) predicts poorer overall and disease-free survival in cholangiocarcinoma, independent of tumor location. These results highlight the potential of PNI as a reliable histopathological marker to stratify postoperative risk and inform patient management. While most evidence is retrospective and smaller studies may overstate the effect, the consistent findings emphasize the need for large, multicenter prospective studies with standardized pathological assessment. Such efforts could facilitate the integration of PNI into prognostic models and support more individualized treatment strategies for patients with cholangiocarcinoma., S.C. is supported by a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (JDC2023-050981-I). N.T. is supported by a La Pedrera MD-PhD fellowship from the Fundació Catalunya La Pedrera. T.M. is supported by grants from the Spanish Institute of Carlos III (PI20/00898, PI24/00526, FORT23/00034), EU TRANSCAN-3, and PerMed projects. T.V.T. is supported by grants from the Spanish Ministry of Science, Innovation and Universities (PID2023-146827OB-I00), “Ramon y Cajal” program (RYC2020-029098-I), FERO Foundation, Fundación AstraZeneca “Jóvenes Investigadores” program, and Cancer Core Europe TRYTRAC program.